摘要: The goal of targeted therapy is to kill cells bearing specific receptors. This in contradistinction cytotoxic chemotherapy, which depends on biochemical differences between normal and target cells. Many types malignant cells, including those resistant display unique proteins the cell surface, making such potentially sensitive therapy. Unlike small chemotherapeutic agents, enter by passing though membrane, must through receptors or antigens surface. Because sites number only thousands per cell, agent be extremely potent. Typically, protein toxins are used since they catalytic mechanisms. In fact, it has been shown with both bacterial plant that one molecule cytoplasm sufficient (CARRASCO et al. 1975; YAMAIZUMI 1978; WILLINGHAM, FITZGERALD PASTAN unpublished data).
springer.com
sci-hub.st 参考文章(73)
RJ Kreitman, CB Siegall, DJ FitzGerald, J Epstein, B Barlogie, I Pastan, Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood. ,vol. 79, pp. 1775- 1780 ,(1992) , 10.1182/BLOOD.V79.7.1775.1775
M.Z. Kounnas, R.E. Morris, M.R. Thompson, D.J. FitzGerald, D.K. Strickland, C.B. Saelinger, The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A Journal of Biological Chemistry. ,vol. 267, pp. 12420- 12423 ,(1992) , 10.1016/S0021-9258(18)42291-0
Janendra K Batra, David FitzGerald, M Gately, Vijay K Chaudhary, Ira Pastan, Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells. Journal of Biological Chemistry. ,vol. 265, pp. 15198- 15202 ,(1990) , 10.1016/S0021-9258(18)77241-4
Gisela Schwab, Richard P. Nordan, Clay B. Siegall, David J. FitzGerald, Ira Pastan, Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Research. ,vol. 50, pp. 7786- 7788 ,(1990)
K. Takatsuki, K. Shirono, T. Hattori, K. Yamaguchi, T. Kiyokawa, H. Nishimura, J. R. Murphy, T. B. Strom, J. C. Nichols, Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Research. ,vol. 49, pp. 4042- 4046 ,(1989)
S Jagannath, DH Vesole, L Glenn, J Crowley, B Barlogie, Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood. ,vol. 80, pp. 1666- 1672 ,(1992) , 10.1182/BLOOD.V80.7.1666.BLOODJOURNAL8071666
Vijay K Chaudhary, Yosihiro Jinno, Maria G Gallo, David FitzGerald, Ira Pastan, Mutagenesis of Pseudomonas exotoxin in identification of sequences responsible for the animal toxicity. Journal of Biological Chemistry. ,vol. 265, pp. 16306- 16310 ,(1990) , 10.1016/S0021-9258(17)46223-5
R K Puri, J P Siegel, P T Mehrotra, I Pastan, R J Kreitman, P Leland, A chimeric protein comprised of IL-4 and Pseudomonas exotoxin is cytotoxic for activated human lymphocytes. Journal of Immunology. ,vol. 152, pp. 3693- 3700 ,(1994)
T A Waldmann, The interleukin-2 receptor. Journal of Biological Chemistry. ,vol. 266, pp. 2681- 2684 ,(1991) , 10.1016/S0021-9258(18)49895-X
P.J. Nicholls, V.G. Johnson, S.M. Andrew, H.R. Hoogenboom, J.C. Raus, R.J. Youle, Characterization of single-chain antibody (sFv)-toxin fusion proteins produced in vitro in rabbit reticulocyte lysate. Journal of Biological Chemistry. ,vol. 268, pp. 5302- 5308 ,(1993) , 10.1016/S0021-9258(18)53533-X